Evidence map›Paper›PMID 40060213›Full record

ArticleCJC open2025

First-in-Human Abdominal Aortic Aneurysms Trial with Tricaprin (F-HAAAT): Study Design and Protocol.

Takahito Kamba, Masahiro Yanagawa, Kazuo Shimamura, Satoshi Yamaguchi, Kenji Shirakura, Satomi Okamura, Yuki Nishimura, Tomomi Yamada, Yasushi Sakata, Noriyuki Tomiyama and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takahito KambaLaboratory of Cardiovascular Disease, Novel, Non-Invasive, and Nutritional Therapeutics (CNT), Department of Triglyceride Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
Masahiro YanagawaDepartment of Radiology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kazuo ShimamuraDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Satoshi YamaguchiTochino Foundation, Osaka, Japan.
Kenji ShirakuraMedical Center for Translational Research, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
Satomi OkamuraData Coordinating Center, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
Yuki NishimuraData Coordinating Center, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
Tomomi YamadaData Coordinating Center, Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
Yasushi SakataDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Noriyuki TomiyamaDepartment of Radiology, Osaka University Graduate School of Medicine, Osaka, Japan.
Shigeru MiyagawaDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Ken-Ichi HiranoLaboratory of Cardiovascular Disease, Novel, Non-Invasive, and Nutritional Therapeutics (CNT), Department of Triglyceride Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
Nobuhiro ZaimaThe Laboratory of Applied Cell Biology, Faculty of Agriculture, Kindai University, Nara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 2%-12% of individuals aged > 65 years worldwide are estimated to have an abdominal aortic aneurysm (AAA), with a mortality rate exceeding 60% in rupture cases. The sole preventive intervention against rupture is timely surgery, which requires substantial medical resources, including postoperative complication management. Although numerous randomized clinical trials have been performed, no oral medication effectively treats AAA. Tricaprin, a medium-chain triglyceride with 3 capric acids, is used in dietary therapy for metabolic and neurological disorders. Our group recently reported that tricaprin, unlike other medium-chain triglycerides, showed reverse remodelliing of AAA in a rat model. Determining whether this basic finding could be translated to clinical practice is important. The

Identifiers

PMID40060213
PMCPMC11886361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.